Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs

 
• By Jessica Merrill

New safety information may help defense of CMS's coverage restrictions. FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported in a trial.

Aduhelm's prescribing information was updated by FDA • Source: Alamy

More from Drug Safety

More from Pink Sheet